UV Phototherapy

WhatsApp Order
UV Phototherapy delivers controlled ultraviolet radiation for treatment of psoriasis, eczema, vitiligo, cutaneous T-cell lymphoma, and pruritus. Narrowband UVB (311-313 nm) is the most common modality, offering effective treatment with minimal systemic side effects. Full-body cabinets, handheld units, and targeted devices allow treatment of localized or widespread disease. Regular phototherapy can achieve significant disease clearance, improve quality of life, and reduce reliance on systemic medications.
Description

UV Phototherapy

PRIMARY CLINICAL & DIAGNOSTIC USES

1. Treatment of Psoriasis
  • Primary Use: Delivers controlled ultraviolet radiation (UVB, narrowband UVB, or PUVA) to reduce inflammation and slow the rapid growth of skin cells characteristic of psoriasis. Narrowband UVB (311-313 nm) is the most commonly used modality for widespread plaque psoriasis.
  • How it helps: For the dermatologist, UV phototherapy provides a highly effective, non-systemic treatment option for patients with moderate to severe psoriasis—reducing the need for systemic medications with their associated side effects. For the patient, regular phototherapy can achieve significant clearance of psoriatic plaques without the risks of immunosuppressive drugs.
2. Treatment of Eczema and Atopic Dermatitis
  • Primary Use: UV phototherapy reduces inflammation, pruritus, and skin thickening associated with atopic dermatitis and other forms of eczema. Narrowband UVB is effective for chronic, widespread eczema that has not responded to topical treatments.
  • How it helps: For the dermatologist managing patients with chronic eczema, phototherapy offers a safe, effective option for patients who have failed topical therapies—reducing the need for systemic immunosuppressants. For the patient, this means relief from intense itching and skin inflammation without the long-term risks of oral medications.
3. Treatment of Vitiligo
  • Primary Use: Narrowband UVB phototherapy stimulates melanocyte proliferation and migration, leading to repigmentation of depigmented patches in vitiligo. Treatment is typically combined with topical corticosteroids or calcineurin inhibitors for enhanced results.
  • How it helps: For the dermatologist, phototherapy is the first-line treatment for widespread vitiligo, offering the best chance for repigmentation without systemic side effects. For the patient with vitiligo, consistent phototherapy can lead to significant repigmentation, improving appearance and quality of life.
4. Treatment of Mycosis Fungoides (Cutaneous T-cell Lymphoma)
  • Primary Use: PUVA (psoralen plus UVA) and narrowband UVB are used to treat early-stage mycosis fungoides, the most common form of cutaneous T-cell lymphoma. UV phototherapy targets malignant T-cells in the skin while sparing systemic treatment.
  • How it helps: For the dermatologist and oncologist, phototherapy provides an effective, skin-directed treatment for early-stage cutaneous lymphoma—potentially avoiding or delaying the need for systemic chemotherapy. For the patient, this means effective disease control with fewer systemic side effects.
5. Treatment of Pruritus and Other Inflammatory Skin Conditions
  • Primary Use: UV phototherapy effectively treats pruritus associated with chronic kidney disease (uremic pruritus), polycythemia vera, and other systemic conditions. It also benefits patients with lichen planus, pityriasis rosea, and other inflammatory dermatoses.
  • How it helps: For the clinician, phototherapy offers a non-pharmacologic option for managing severe itching in patients who may have contraindications to antipruritic medications. For the patient, relief from chronic pruritus significantly improves sleep, mood, and overall quality of life.

SECONDARY & SUPPORTIVE USES

1. Treatment of Morphea and Scleroderma: UV phototherapy for localized scleroderma.
2. Treatment of Cutaneous Graft-Versus-Host Disease: UV phototherapy for skin manifestations of GVHD.
3. Treatment of Polymorphous Light Eruption: UV hardening for photosensitive disorders.
4. Treatment of Prurigo Nodularis: Reduction of nodules and itching.
5. Treatment of Palmoplantar Pustulosis: UV phototherapy for pustular psoriasis of hands and feet.
6. Treatment of Alopecia Areata: Limited evidence; used as adjunct therapy.
KEY PRODUCT FEATURES

1. BASIC IDENTIFICATION ATTRIBUTES

  • Device Type: A phototherapy system that delivers controlled ultraviolet radiation for treatment of dermatologic conditions.
  • Designation: UV Phototherapy, Narrowband UVB, PUVA, Ultraviolet Phototherapy, Phototherapy Unit.
  • Types:
    • Narrowband UVB: 311-313 nm wavelength; most common for psoriasis and eczema.
    • Broadband UVB: 290-320 nm; less commonly used due to higher risk of burning.
    • PUVA: Psoralen plus UVA (320-400 nm); used for more severe conditions.
    • UVA1: 340-400 nm; for scleroderma, atopic dermatitis, and cutaneous T-cell lymphoma.
  • Key Components:
    • Lamp Array: Fluorescent tubes or LED emitters.
    • Control Unit: Timer, dose calculation, and treatment parameters.
    • Cabinets: Full-body units, handheld units, or targeted units.
    • UV Meter: For dose calibration.
    • Eye Protection: UV-blocking goggles for patient safety.
    • Safety Interlocks: Door and position sensors.

2. TECHNICAL & PERFORMANCE PROPERTIES

  • Wavelength: 311-313 nm (narrowband UVB); 320-400 nm (UVA).
  • Treatment Frequency: 2-3 times per week.
  • Dosing: Measured in mJ/cm² or J/cm².
  • Treatment Duration: Minutes per session depending on dose.
  • Maximum Dose: Determined by skin type and treatment response.
  • Lamp Life: 500-1000 hours depending on type.

3. PHYSICAL & OPERATIONAL PROPERTIES

  • Configuration: Full-body cabinets, handheld units, or targeted units.
  • Portability: Stationary or mobile depending on model.
  • Controls: Digital interface with dose calculation and patient records.
  • Safety: Emergency shut-off, door interlocks, UV-blocking viewing windows.

4. SAFETY & COMPLIANCE ATTRIBUTES

  • Regulatory Status: Class II medical device regulated by FDA.
  • Eye Protection: UV-blocking goggles required for patient and operator.
  • Skin Protection: Shield non-treated areas; use genital protection.
  • Contraindications: History of skin cancer, photosensitivity disorders, certain medications (photosensitizing).
  • Adverse Effects: Erythema (sunburn), pruritus, xerosis, photoaging, increased skin cancer risk with long-term use.
  • Safety Standards: Compliant with medical device safety standards.

5. STORAGE & HANDLING ATTRIBUTES

  • Storage: Stored in the treatment room; protect lamps from damage.
  • Cleaning: Clean lamp surfaces and cabinets per manufacturer guidelines.
  • Maintenance: Regular lamp calibration; record lamp hours; replace bulbs at end of life.
  • Calibration: UV meter calibration per manufacturer schedule.

6. LABORATORY & CLINICAL APPLICATIONS

  • Primary Application: Treatment of psoriasis, eczema, vitiligo, cutaneous T-cell lymphoma, and pruritus.
  • Clinical Role: Used in dermatology practices, phototherapy centers, and hospital outpatient departments.
SAFETY HANDLING PRECAUTIONS

1. SAFETY PRECAUTIONS

  • Eye Protection: Patients must wear UV-blocking goggles during all exposures.
  • Skin Assessment: Assess skin type and history of photosensitivity before treatment.
  • Medication Review: Review for photosensitizing medications.
  • Dose Titration: Start with sub-erythemogenic dose; increase gradually based on tolerance.
  • Treatment Interruption: Reduce dose after missed treatments to prevent burning.
  • Skin Cancer Surveillance: Monitor for skin cancer in long-term phototherapy patients.

2. FIRST AID MEASURES

  • Burn: If erythema is severe or blistering occurs, discontinue treatment; apply cool compresses; topical corticosteroids; seek medical attention if severe.
  • Eye Exposure: If UV exposure occurs without protection, assess for symptoms; refer to ophthalmology if needed.

3. FIRE FIGHTING MEASURES

  • Flammability: Electrical components may pose fire risk.
  • Extinguishing Media: For electrical fire, use COâ‚‚ or dry chemical extinguisher.